Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene BTK Cancer Drug Approved in US for Lymphoma

publication date: Nov 15, 2019

BeiGene, a Beijing oncology biopharma, announced US approval of its Bruton’s tyrosine kinase candidate, Brukinsa™ (zanubrutinib), as a second-line treatment for adult patients with mantle cell lymphoma. Brukinsa is the first BeiGene-discovered product to be approved. The approval was based on the candidate's overall response rate of 84% and complete response of 59%. BeiGene may be asked to conduct a confirmatory trial of Brukinsa. The company expects its second approval before the end of the year for China use of its PD-1 candidate. More details...

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China